CN108354916A - 用于治疗糖尿病和相关病症的方法和组合物 - Google Patents

用于治疗糖尿病和相关病症的方法和组合物 Download PDF

Info

Publication number
CN108354916A
CN108354916A CN201810134012.1A CN201810134012A CN108354916A CN 108354916 A CN108354916 A CN 108354916A CN 201810134012 A CN201810134012 A CN 201810134012A CN 108354916 A CN108354916 A CN 108354916A
Authority
CN
China
Prior art keywords
glutamine
diabetes
salt
level
month
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810134012.1A
Other languages
English (en)
Chinese (zh)
Inventor
新原丰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emmaus Medical Inc
Original Assignee
Emmaus Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48470183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN108354916(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emmaus Medical Inc filed Critical Emmaus Medical Inc
Publication of CN108354916A publication Critical patent/CN108354916A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201810134012.1A 2011-11-21 2012-11-17 用于治疗糖尿病和相关病症的方法和组合物 Pending CN108354916A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161629633P 2011-11-21 2011-11-21
US61/629,633 2011-11-21
CN201280056939.9A CN103945858A (zh) 2011-11-21 2012-11-17 用于治疗糖尿病和相关病症的方法和组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280056939.9A Division CN103945858A (zh) 2011-11-21 2012-11-17 用于治疗糖尿病和相关病症的方法和组合物

Publications (1)

Publication Number Publication Date
CN108354916A true CN108354916A (zh) 2018-08-03

Family

ID=48470183

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201810134012.1A Pending CN108354916A (zh) 2011-11-21 2012-11-17 用于治疗糖尿病和相关病症的方法和组合物
CN201280056939.9A Pending CN103945858A (zh) 2011-11-21 2012-11-17 用于治疗糖尿病和相关病症的方法和组合物
CN201810135122.XA Pending CN108478551A (zh) 2011-11-21 2012-11-17 用于治疗糖尿病和相关病症的方法和组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201280056939.9A Pending CN103945858A (zh) 2011-11-21 2012-11-17 用于治疗糖尿病和相关病症的方法和组合物
CN201810135122.XA Pending CN108478551A (zh) 2011-11-21 2012-11-17 用于治疗糖尿病和相关病症的方法和组合物

Country Status (10)

Country Link
US (2) US20130143968A1 (enExample)
EP (2) EP3437649A1 (enExample)
JP (4) JP6089042B2 (enExample)
CN (3) CN108354916A (enExample)
BR (1) BR112014011898A2 (enExample)
ES (1) ES2785094T3 (enExample)
HK (1) HK1257401A1 (enExample)
IN (1) IN2014KN01037A (enExample)
PH (2) PH12020550726B1 (enExample)
WO (1) WO2013077893A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US10682325B2 (en) 2017-08-14 2020-06-16 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
JP2021527670A (ja) 2018-06-20 2021-10-14 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． 筋肉中の脂肪浸潤の治療のための組成物及び方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
CA2418543A1 (en) * 2001-06-27 2003-01-09 Probiodrug Ag New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
SE0201713D0 (sv) * 2001-11-23 2002-06-06 Gramineer Internat Ab New methods and use III
TWI351278B (en) * 2002-03-01 2011-11-01 Nisshin Pharma Inc Agent for preventing and treating of liver disease
US20070025953A1 (en) * 2005-07-27 2007-02-01 Jones Michael R Co-therapy for diabetic conditions
CA2774197A1 (en) * 2006-04-22 2008-04-03 Harbor Biosciences, Inc. Drugs and uses to modulate inflammation, metabolic disorders and other conditions
WO2008038771A1 (en) * 2006-09-29 2008-04-03 Ajinomoto Co., Inc. Glutamine-containing composition for increasing blood flow
US20080221074A1 (en) * 2006-11-17 2008-09-11 Jaime Flores-Riveros Drug Screen and Treatment Method
EP2057905A1 (en) * 2007-11-12 2009-05-13 TIMA Foundation Composition for moderating Triglyceride and Cholesterol Levels
WO2010081079A2 (en) * 2009-01-12 2010-07-15 Biokier Inc. Composition and method for treatment of diabetes
NL1036746C2 (nl) * 2009-03-20 2010-09-21 Glnp Holding B.V. Kit van onderdelen bevattende l-glutamine en egcg.
JP2013505936A (ja) * 2009-09-23 2013-02-21 バイオキアー・インコーポレイテッド 糖尿病の治療のための組成物および方法

Also Published As

Publication number Publication date
PH12014501052A1 (en) 2014-06-30
JP6550160B2 (ja) 2019-07-24
HK1257401A1 (zh) 2019-10-18
PH12020550726B1 (en) 2022-11-09
EP2782588A1 (en) 2014-10-01
CN108478551A (zh) 2018-09-04
EP2782588B1 (en) 2020-04-15
BR112014011898A2 (pt) 2017-05-16
WO2013077893A1 (en) 2013-05-30
EP2782588A4 (en) 2015-05-20
PH12020550726A1 (en) 2021-06-14
PH12014501052B1 (en) 2020-10-09
US20190192463A1 (en) 2019-06-27
EP3437649A1 (en) 2019-02-06
CN103945858A (zh) 2014-07-23
JP2018115175A (ja) 2018-07-26
IN2014KN01037A (en) 2015-10-09
JP2014533689A (ja) 2014-12-15
JP6089042B2 (ja) 2017-03-01
US20130143968A1 (en) 2013-06-06
JP2017052766A (ja) 2017-03-16
JP6389495B2 (ja) 2018-09-12
ES2785094T3 (es) 2020-10-05
JP2018199692A (ja) 2018-12-20

Similar Documents

Publication Publication Date Title
JP4577985B2 (ja) ジフェニルエチレン化合物の新規な複素環類似体
JP2009532372A (ja) 代謝障害の併用治療
KR101567660B1 (ko) 진성 당뇨병을 치료하기 위한 병용제
US20190192463A1 (en) Methods and compositions for the treatment of diabetes and related systems
JP2017519028A (ja) 重度の高トリグリセリド血症の処置
WO2024032090A1 (zh) 用于改善受试者的脂代谢作用的组合物和方法
JP6412241B2 (ja) 肝機能改善法
BRPI0707670A2 (pt) composiÇço farmacÊutica, e, uso de um composto meglitinida
US20090137626A1 (en) Pharmaceutical Composition Containing PPARgamma Agonist
FR3062795B1 (fr) Principe actif pharmaceutique et utilisation en particulier dans la prevention et le traitement des dereglements metaboliques chez l'homme et l'animal.
US20210251932A1 (en) Method Of Treatment Of Obesity
WO2015062167A1 (zh) Metrnl蛋白在制备降血脂降血糖药物中的应用
FR2823211A1 (fr) Composition a base d'un polyphosphate de s-adenosyl-l-methionine et utilisations d'un tel polyphosphate
CA2614121C (fr) Derives de thiazoles pour traiter les dyskinesies provoquees par un traitement chimique
EP0542979A1 (fr) Composition therapeutique pour liberation prolongee de magnesium
CN117338776A (zh) β-内酰胺类化合物或其盐用于长效预防或治疗葡萄糖代谢失调的用途
US20240382445A1 (en) Methods of adjuvant therapy
JP2006519881A5 (enExample)
ES2379165T3 (es) Uso de un agonista de PPAR-alfa para tratar la ganancia de peso asociada con un tratamiento con un agonista de PPAR-Gamma
CN117653642A (zh) 格列本脲促进nad+水平的用途
HK1111620A (en) Pharmaceutical composition containing ppar gamma agonist

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1257401

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180803

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1257401

Country of ref document: HK